JP2007532671A - アデノシンa1受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法 - Google Patents
アデノシンa1受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法 Download PDFInfo
- Publication number
- JP2007532671A JP2007532671A JP2007508540A JP2007508540A JP2007532671A JP 2007532671 A JP2007532671 A JP 2007532671A JP 2007508540 A JP2007508540 A JP 2007508540A JP 2007508540 A JP2007508540 A JP 2007508540A JP 2007532671 A JP2007532671 A JP 2007532671A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- composition
- substituted
- hydrogen
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Description
[式中、
X1およびX2はそれぞれ独立して酸素または硫黄を表す;
Qは
(式中、Yは単結合または1〜4個の炭素原子を持つアルキレンを表し、nは0または1を表す)
を表す;
R1およびR2はそれぞれ独立して水素、低級アルキル、アリル、プロパルギル、またはヒドロキシ置換、オキソ置換もしくは無置換低級アルキルを表し、R3は水素または低級アルキルを表すか、
R4およびR5は同じであるか相異なって、それぞれ水素またはヒドロキシを表し、R4およびR5がどちらも水素である場合、R1およびR2の少なくとも一方はヒドロキシ置換またはオキソ置換低級アルキルである;
ただし、Qが
である場合、R1、R2およびR3は同時にはメチルでないものとする]。
[式中、R6およびR7は同じであるか相異なって、水素または炭素数1〜4のアルキル基であることができ、R8は酸素であるか(CH2)1-4であり、n=0〜4である]。
であることができる。
Claims (21)
- アルドステロン阻害剤およびアデノシンA1受容体アンタゴニスト(AA1RA)を含む医薬組成物。
- 前記アルドステロン阻害剤が、スピロノラクトンおよびエプレレノンから選択されるか、または医薬的に許容できるその塩、プロドラッグ、エステル、もしくはアミドである、請求項1記載の組成物。
- 前記AA1RAが、式Iのキサンチン誘導体化合物またはその医薬的に許容できる塩である、請求項1記載の組成物:
[式中、
X1およびX2はそれぞれ独立して酸素または硫黄を表し;
Qは
(式中、Yは単結合または1〜4個の炭素原子を持つアルキレンを表し、nは0または1を表す)
を表し;
R1およびR2はそれぞれ独立して水素、低級アルキル、アリル、プロパルギル、またはヒドロキシ置換、オキソ置換もしくは無置換低級アルキルを表し、R3は水素または低級アルキルを表すか、
R4およびR5は同じであるか相異なって、それぞれ水素またはヒドロキシを表し、R4およびR5がどちらも水素である場合、R1およびR2の少なくとも一方はヒドロキシ置換またはオキソ置換低級アルキルである;
ただし、Qが
である場合、R1、R2およびR3は同時にはメチルでないものとする]。 - 前記R1およびR2がどちらも低級アルキルであり、R3が水素であり、X1およびX2がどちらも酸素である請求項3記載の組成物。
- 前記R1、R2およびR3が独立して水素または低級アルキルである、請求項3記載の組成物。
- 前記R1およびR2がそれぞれ独立してアリルまたはプロパルギルであり、R3が水素または低級アルキルである請求項3記載の組成物。
- 前記R1がヒドロキシ置換、オキソ置換または無置換プロピルであり、R2がヒドロキシ置換または無置換プロピルであり、Yが単結合である請求項3記載の組成物。
- R1がプロピル、2-ヒドロキシプロピル、2-オキソプロピルまたは3-オキソプロピルであり、R2がプロピル、2-ヒドロキシプロピルまたは3-ヒドロキシプロピルである請求項3記載の組成物。
- 前記X1およびX2がどちらも酸素であり、nが0である請求項6記載の組成物。
- 前記Qが
である請求項5記載の組成物。 - 前記Qが
- Qが、9-ヒドロキシ、9-オキソまたは6-ヒドロキシ置換3 トリシクロ[3.3.1.03,7]ノニル、または3-ヒドロキシ-1 トリシクロ[3.3.1.13,7]デシルである請求項5記載の組成物。
- 前記AA1RAが、8-(ノルアダマンタン-3-イル)-1,3-ジプロピルキサンチン、1,3-ジアリル-8-(3-ノルアダマンチル)キサンチン、3-アリル-8-(3-ノルアダマンチル)-1-プロパルギルキサンチン、8-(trans-9-ヒドロキシ-3-トリシクロ[3.3.1.03,7]ノニル)-1,3-ジプロピルキサンチン、8-(cis-9-ヒドロキシ-3-トリシクロ[3.3.1.03,7]ノニル)-1,3-ジプロピルキサンチン、8-(trans-9-ヒドロキシ-3-トリシクロ[3.3.1.03,7]ノニル)-1-(2-オキソプロピル)-3-プロピルキサンチンおよび1-(2-ヒドロキシプロピル)-8-(trans-9-ヒドロキシ-3-トリシクロ[3.3.1.03,7]ノニル)-3-プロピルキサンチンからなる群より選択されるか、または医薬的に許容されるそれらの塩である、請求項1記載の組成物。
- AA1RAが、式IIもしくは式IIIのキサンチンエポキシド誘導体化合物、または医薬的に許容できるその塩である請求項1記載の組成物:
[式中、R6およびR7は同じであるか相異なって、水素または炭素数1〜4のアルキル基であることができ、R8は酸素であるか(CH2)1-4であり、n=0〜4である]。 - 前記キサンチンエポキシド誘導体化合物が、
- 心血管疾患を処置する方法であって、そのような処置を必要とする患者を同定する工程、および請求項1記載の医薬組成物を該患者に投与する工程を含む方法。
- 前記投与工程が、前記アルドステロン阻害剤と前記AA1RAとをほぼ同時に投与することを含む請求項16に記載の方法。
- 前記投与工程が、AA1RAかアルドステロン阻害剤のいずれか一方を最初に投与し、次にAA1RAかアルドステロン阻害剤の他方を投与することを含む請求項16記載の方法。
- 前記心血管疾患が、うっ血性心不全、高血圧、無症候性左心室機能障害、または冠動脈疾患である請求項16記載の方法。
- 前記患者が、後負荷軽減を必要とするものである請求項16記載の方法。
- 前記患者が、追加の利尿薬療法を必要とするか、利尿薬療法では効果のない患者である請求項16記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56316604P | 2004-04-16 | 2004-04-16 | |
PCT/US2005/012724 WO2005105083A1 (en) | 2004-04-16 | 2005-04-14 | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007532671A true JP2007532671A (ja) | 2007-11-15 |
JP2007532671A5 JP2007532671A5 (ja) | 2008-05-29 |
Family
ID=34965807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007508540A Withdrawn JP2007532671A (ja) | 2004-04-16 | 2005-04-14 | アデノシンa1受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20050239759A1 (ja) |
EP (1) | EP1755594A1 (ja) |
JP (1) | JP2007532671A (ja) |
KR (1) | KR20070008689A (ja) |
CN (1) | CN101094671A (ja) |
AU (1) | AU2005237466A1 (ja) |
BR (1) | BRPI0509753A (ja) |
CA (1) | CA2568436A1 (ja) |
MX (1) | MXPA06011823A (ja) |
WO (1) | WO2005105083A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060293312A1 (en) * | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
NZ543109A (en) * | 2003-04-25 | 2008-06-30 | Novacardia Inc | Method of improved diuresis in individuals with impaired renal function |
WO2007117549A2 (en) * | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine a1 receptor antagonists and anticonvulsants |
EP2035009A1 (en) * | 2006-06-16 | 2009-03-18 | Novacardia, Inc. | Prolonged improvement of renal function comprising infrequent administration of an aa1ra |
JP2010501557A (ja) * | 2006-08-22 | 2010-01-21 | ノヴァカーディア,インク. | 血液脳関門を通過しないkw−3902コンジュゲート |
US20080242684A1 (en) * | 2007-03-29 | 2008-10-02 | Howard Dittrich | Methods of administration of adenosine a1 receptor antagonists |
US20090197900A1 (en) * | 2007-03-29 | 2009-08-06 | Howard Dittrich | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
WO2018153898A1 (de) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE416810C (sv) * | 1977-10-14 | 1982-05-11 | Draco Ab | Forfarande for framstellning av xantinderivat med antiallergisk aktivitet |
FR2531085A1 (fr) * | 1982-07-28 | 1984-02-03 | Adir | Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
DE8817122U1 (ja) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 6507 Ingelheim, De | |
US5290782A (en) * | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
DE4238367A1 (de) * | 1992-11-13 | 1994-05-19 | Boehringer Ingelheim Kg | Diuretisches Mittel |
US5395836A (en) * | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
US5446046A (en) * | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
US5736528A (en) * | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
ATE240734T1 (de) * | 1995-07-26 | 2003-06-15 | Kyowa Hakko Kogyo Kk | Zubereitung von xanthinderivaten als feste dispersion |
EP0958821B1 (en) * | 1996-08-07 | 2004-11-10 | Kyowa Hakko Kogyo Co., Ltd. | Fat emulsion containing xanthine derivative |
US6117445A (en) * | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
US6187780B1 (en) * | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
AU3757999A (en) * | 1998-04-24 | 1999-11-16 | Biogen, Inc. | Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function |
US20020115687A1 (en) * | 1998-04-24 | 2002-08-22 | Evan Beckman | Method and composition for restoring diuretic and renal function |
EP0970696A1 (en) * | 1998-05-05 | 2000-01-12 | Kyowa Hakko Kogyo Co., Ltd. | Combination of loop diuretics with adenosine A1-receptor antagonists |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
US20050250748A1 (en) * | 1999-03-05 | 2005-11-10 | G. D. Searle & Co. | Combination therapy of angiotensin converting enzyme inhibitor and eplerenone for treatment of cardiovascular disease |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
NZ543109A (en) * | 2003-04-25 | 2008-06-30 | Novacardia Inc | Method of improved diuresis in individuals with impaired renal function |
-
2005
- 2005-04-14 BR BRPI0509753-3A patent/BRPI0509753A/pt not_active IP Right Cessation
- 2005-04-14 JP JP2007508540A patent/JP2007532671A/ja not_active Withdrawn
- 2005-04-14 AU AU2005237466A patent/AU2005237466A1/en not_active Abandoned
- 2005-04-14 KR KR1020067023348A patent/KR20070008689A/ko not_active Application Discontinuation
- 2005-04-14 EP EP05735398A patent/EP1755594A1/en not_active Withdrawn
- 2005-04-14 WO PCT/US2005/012724 patent/WO2005105083A1/en active Application Filing
- 2005-04-14 CN CNA2005800123693A patent/CN101094671A/zh active Pending
- 2005-04-14 MX MXPA06011823A patent/MXPA06011823A/es not_active Application Discontinuation
- 2005-04-14 CA CA002568436A patent/CA2568436A1/en not_active Abandoned
- 2005-04-14 US US11/107,637 patent/US20050239759A1/en not_active Abandoned
-
2009
- 2009-06-16 US US12/485,797 patent/US20090253665A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA06011823A (es) | 2006-12-15 |
EP1755594A1 (en) | 2007-02-28 |
US20090253665A1 (en) | 2009-10-08 |
WO2005105083A1 (en) | 2005-11-10 |
AU2005237466A1 (en) | 2005-11-10 |
BRPI0509753A (pt) | 2007-10-16 |
KR20070008689A (ko) | 2007-01-17 |
CA2568436A1 (en) | 2005-11-10 |
CN101094671A (zh) | 2007-12-26 |
US20050239759A1 (en) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060030572A1 (en) | Method of improved diuresis in individuals with impaired renal function | |
US20090253665A1 (en) | Method of treatment of disease using an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
US7834056B2 (en) | Pharmaceutical composition for gout | |
JP2009539996A (ja) | 腎機能障害を持つ個体における利尿改善方法 | |
US20070238672A1 (en) | Co-administration of adenosine a1 receptor antagonists and anticonvulsants | |
AU2004216133B2 (en) | Adenosine A1 receptor antagonist for the treatment of cardiac and renal diseases | |
JP2010501557A (ja) | 血液脳関門を通過しないkw−3902コンジュゲート | |
JP4542777B2 (ja) | 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用 | |
US20080242684A1 (en) | Methods of administration of adenosine a1 receptor antagonists | |
EP1932529A1 (en) | Method of improved diuresis in individuals with impaired renal function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080410 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080410 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090403 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090403 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100205 |